Antiphospholipid syndrome and thrombosis.

Area of Science:

• Hematology
• Immunology
• Vascular Medicine

Background:

• Antiphospholipid antibodies (aPL) are acquired blood defects strongly associated with thrombosis.
• The exact mechanisms by which aPL induce a hypercoagulable state are not fully understood.
• aPL are implicated in various thrombotic syndromes, including venous, arterial, and pregnancy-related complications.

Purpose of the Study:

• To highlight the association between antiphospholipid antibodies and thrombosis.
• To emphasize the importance of diagnosing antiphospholipid syndrome for effective treatment.
• To outline diagnostic approaches and therapeutic strategies for aPL-associated thrombosis.

Main Methods:

• Review of clinical presentations and diagnostic criteria for antiphospholipid syndrome.
• Discussion of laboratory tests for detecting antiphospholipid antibodies (ACLA, lupus anticoagulant, anti-beta-2-glycoprotein I).
• Evaluation of treatment outcomes with different anticoagulant and antiplatelet therapies.

Main Results:

• Antiphospholipid antibodies are a common cause of acquired thrombotic events.
• Specific syndromes (Types I-VI) are associated with different thrombotic manifestations.
• Standard anticoagulants like warfarin and antiplatelet agents are often ineffective, necessitating therapies like heparin.

Conclusions:

• Early identification of antiphospholipid antibodies is critical in unexplained thrombosis.
• Accurate diagnosis of antiphospholipid syndrome guides appropriate anticoagulant therapy selection.
• Low-molecular-weight heparin or unfractionated heparin are often the most effective treatments for secondary prevention.